Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast
Cancer Risk Prediction in Women with Atypia
ROCHESTER, Minn., July 2, 2007-Women with at least three sites ofcellular atypia in breast tissue are nearly eight times more likelythan average women to develop breast cancer, according to findingsof a Mayo Clinic Cancer Center led study of women with atypicalhyperplasia. The findings are published in the July 1 issue of theJournal of Clinical Oncology. Several previous studies have show...
ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical
Model
KOS, Greece--(BUSINESS WIRE)--Jun 26, 2007 - Acceleron Pharma,Inc., a biopharmaceutical company developing therapeutics for thetreatment of musculoskeletal, metabolic and cancer-relateddiseases, today announced results demonstrating that ACE-011, anovel anabolic bone agent for the treatment of bone loss, preservedbone mass and architecture in a murine model of multiple myeloma.Multiple myel...
Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal
Women with Early Breast Cancer Receiving Treatment with Tamoxifen
Survival Benefit Demonstrated for an AI Over Tamoxifen ina Single Trial LUTON, UK, Friday 15 June 2007: Analysis of the entirepopulation of a single trial has demonstrated that survival inearly breast cancer can be significantly improved by switching fromtamoxifen to anastrozole (Arimidex). An analysis of the'Arimidex'-'Nolvadex 95' (ARNO 95) study, published online in TheJourna...
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid
Arthritis Compared to a Current Standard of Care
NUTLEY, N.J., June 15, 2007 /PRNewswire/ -- Results of theOption (TOcilizumab Pivotal Trial in Methotrexate InadequaterespONders) trial, the first multinational Phase III study outsideof Japan, showed that patients treated with Actemra (either 4mg/kgor 8mg/kg) plus methotrexate achieved a significant and clinicallyimportant improvement in the signs and symptoms of moderate tosevere rheum...
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and
Maintenance vs. Placebo
Demonstrates Positive Effect on Objective and Subjective SleepMeasures MINNEAPOLIS, June 13, 2007 /PRNewswire-FirstCall/ -- Accordingto study results presented today at SLEEP 2007, the 21st annualmeeting of the Associated Professional Sleep Societies (APSS),VEC-162, a balanced melatonin (MT1/MT2) receptor agonist beingdeveloped by Vanda Pharmaceuticals Inc. , demonstrated improvementsin...
Ivivi's PEMF Technology Significantly Improves Neuron Survival in
Parkinson's Disease Model, Study Finds
NORTHVALE, N.J.--(BUSINESS WIRE)--Jun 12, 2007 - Proprietary PulsedElectromagnetic Field (PEMF) technology, developed by IviviTechnologies, Inc. (AMEX:II), improved neuron survival in astandard animal cell model of brain inflammation, researchersreported today in a platform presentation at theBioelectromagnetics Society (BEMS,http://www.bioelectromagnetics.org) Annual Meeting, in Kanazawa,...
Study Shows Velcade Plus Doxil Improves Survival in Previously
Treated Patients With Multiple Myeloma
Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...
Adding Thalidomide to Standard Therapy Improves Survival in Newly
Diagnosed Multiple Myeloma Patients Over Age 75
Phase III Clinical Data on Thalidomide in Multiple MyelomaPresented at the American Society of Clinical Oncology 43rd AnnualMeeting CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- PharmionCorporation today reported the final results of a Phase III studydemonstrating that the addition of Thalidomide to standard therapy
improves overall survival (OS) by 17.6 months in patients aged 75or ol...
First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A)
Significantly Improves Idiopathic Detrusor Overactivity (IDO) in
Patients With Symptoms of Overactive Bladder
Treatment Benefits Were Maintained for at Least 24 Weeks, Accordingto Report Published in The Journal of Urology LONDON, May 15, 2007 /PRNewswire/ -- Researchers from Guy'sHospital and King's College London School of Medicine haveannounced the results from the first randomized, double-blind,placebo-controlled study evaluating botulinum toxin type A (BTX-A,BOTOX(R)) as a treatment for idio...
Newly Published Study Reveals Femara Improves Chances for Harder to
Treat Early Breast Cancer Relapse in Postmenopausal Women
FRIMLEY, SURREY, England, April 30, 2007 /PRNewswire-FirstCall/-- - Femara reduces the risk of breast cancer spreading to thelungs, the brain or the bone which has a worse prognosis than whenthe cancer is localised to the breast Newly published data in the May issue of Annals of Oncology,Oxford University Press show that after two years of post-surgicaltherapy, postmenopausa...
Once Daily, Extended-Release Ropinirole Improves Parkinson's
Symptoms in Patients not Optimally Controlled With Levodopa
'Off' Time Reduced By an Average of More Than Two Hours Per Day RESEARCH TRIANGLE PARK, N.C., April 02, 2007 /PRNewswire/ --Adding the once daily, investigational medication REQUIP(R)(ropinirole HCl) XL 24-Hour(TM) Extended-Release Tablets toParkinson's patients' existing levodopa (L-dopa) therapysignificantly reduced 'off' time, allowing patients to continuetheir daily activities for a l...